Hartmann F - Search Results

1

Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.

Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M. Sahin U, et al. Among authors: hartmann f. Cancer Res. 1990 Nov 1;50(21):6944-8. Cancer Res. 1990. PMID: 2170012

2

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.

Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M. Renner C, et al. Among authors: hartmann f. Science. 1994 May 6;264(5160):833-5. doi: 10.1126/science.8171337. Science. 1994. PMID: 8171337

3

Treatment of Hodgkin's disease with bispecific antibodies.

Hartmann F, Renner C, Jung W, Sahin U, Pfreundschuh M. Hartmann F, et al. Ann Oncol. 1996;7 Suppl 4:143-6. doi: 10.1093/annonc/7.suppl_4.s143. Ann Oncol. 1996. PMID: 8836426 Review.

4

Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.

Renner C, Hartmann F, Pfreundschuh M. Renner C, et al. Among authors: hartmann f. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):184-6. doi: 10.1007/s002620050428. Cancer Immunol Immunother. 1997. PMID: 9435869 Free PMC article. Clinical Trial.

5

Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.

Hartmann F, Renner C, Jung W, Pfreundschuh M. Hartmann F, et al. Leuk Lymphoma. 1998 Oct;31(3-4):385-92. doi: 10.3109/10428199809059232. Leuk Lymphoma. 1998. PMID: 9869203 Clinical Trial.

6

Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.

Renner C, Hartmann F, Jung W, Deisting C, Juwana M, Pfreundschuh M. Renner C, et al. Among authors: hartmann f. Cancer Immunol Immunother. 2000 Jun;49(3):173-80. doi: 10.1007/s002620050617. Cancer Immunol Immunother. 2000. PMID: 10881697 Free PMC article. Clinical Trial.

7

[Prognosis and therapy of Hodgkin's disease].

Hartmann F, Pfreundschuh M, Diehl V. Hartmann F, et al. Med Klin (Munich). 1996 Apr 12;91 Suppl 3:75-9. Med Klin (Munich). 1996. PMID: 8692124 Review. German. No abstract available.

8

Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.

Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M. Hartmann F, et al. Blood. 1997 Mar 15;89(6):2042-7. Blood. 1997. PMID: 9058726 Free article. Clinical Trial.

9

Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.

da Costa L, Renner C, Hartmann F, Pfreundschuh M. da Costa L, et al. Among authors: hartmann f. Cancer Chemother Pharmacol. 2000;46 Suppl:S33-6. doi: 10.1007/pl00014047. Cancer Chemother Pharmacol. 2000. PMID: 10950145 Clinical Trial.

10

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.

Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, König J, Bauer S, Kloft M, Pfreundschuh M. Hartmann F, et al. Clin Cancer Res. 2001 Jul;7(7):1873-81. Clin Cancer Res. 2001. PMID: 11448899 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,197 results

Search Page

Filters